![]() | ![]() |
Formats:
|
||||||||||||||||||||||
Multiplexed Detection Methods for Profiling microRNA Expression in Biological Samples Department of Chemistry, University of California-Irvine, Irvine, CA 92697, USA *Prof. R. M. Corn, 1102 Natural Sciences 2, Fax: + (1) 949 824 8571, rcorn/at/uci.edu, Website: http://www.corninfo.ps.uci.edu/ The publisher's final edited version of this article is available at Angew Chem Int Ed Engl.Abstract Lead-in The recent discovery of short, non-protein coding RNA molecules such as microRNAs (miRNAs) that can control gene expression has unveiled a whole new layer of complexity in the regulation of cell function. Since 2001, there has been a surge of interest in understanding the regulatory role of the hundreds to thousands of miRNAs expressed in both plants and animals. Significant progress in this area requires the development of quantitative bioanalytical methods for the rapid, multiplexed detection of all miRNAs present in a particular cell or tissue sample. In this Minireview, we discuss some of the latest methods for high-throughput miRNA profiling and the unique technological challenges that must be surmounted in this endeavor. Keywords: Microarray, microRNA, miRNA, profiling, RNA silencing I. Introduction MicroRNAs (miRNAs) are a class of small (~19-23 nucleotides), non-protein coding RNA molecules found in a broad range of plants, viruses and mammals. miRNAs are initially transcribed in the cell nucleus as long precursors (pri-miRNA) that are enzymatically processed into ~70 nucleotide stem-loop structures (pre-miRNA), which are then exported into the cell cytoplasm. A second enzymatic processing step creates ~22 nucleotide long mature miRNAs. These mature miRNAs can regulate gene expression following incorporation into an active RNA-induced silencing complex (RISC) where they interact with complementary sites on messenger RNA molecules resulting in translational repression and sometimes degradation of the target messenger RNA. While identification of the characteristic stem-loop structure of pre-miRNA is important for miRNA classification,[1] it is the expression level of the mature form that is of most interest to researchers investigating the biological function of miRNAs. There are a number of good reviews available on the mechanism of gene regulation and silencing by miRNAs.[2-6] Although the first published description of a miRNA appeared more than a decade ago,[7] the importance of miRNA in gene regulation and cell function is just beginning to be understood. Studies in model organisms have shown miRNAs are involved in the regulation of many critical biological processes such as development, differentiation, metabolism and immunological response.[8-10] Recently, several research groups have established links between alterations in the expression levels of miRNAs and the initiation and development of human cancers.[11, 12] Comparative analyses between various malignant and normal tissue samples revealed characteristic patterns, where some miRNAs are overexpressed and others strongly repressed, that depended on the cancer type, disease stage and response to treatment.[12] Also, miRNA expression levels have been shown to play a controlling role in tumor growth rates suggesting possible new strategies for therapeutic treatment.[13] A key approach emerging in the investigation of the cellular roles of miRNAs is to profile the mature miRNA expression levels in specific tissue types at various developmental or disease stages. For this reason, considerable effort has been devoted to the development of new methods for high throughput, multiplexed miRNA gene expression analysis. Currently, over 4500 miRNA sequences are listed in the miRNA Registry,[14, 15] including 475 human miRNAs. The total number of miRNAs in the human genome is not yet known, but estimates based on computational analyses range up to 1000.[2, 16] Recently, Tuschl and colleagues published one of the most comprehensive survey of mammalian miRNA expression patterns to date where they used a variety of experimental and computational methods to analyze miRNA expression profiles from 26 different organ systems and cell types of humans and rodents.[17] A timeline for miRNA discovery and detection is shown in Figure 1
In recent years, these multiplexed single miRNA methods have been supplanted by the use of oligonucleotide microarray-based detection platforms as the most efficient approach to miRNA high-throughput profiling.[23-32] Complementary DNA (cDNA) microarrays for the multiplexed detection of messenger RNA molecules have proven to be extremely valuable for the study of gene expression in biological samples[33]; in a similar fashion, the population of known miRNA molecules should in principle be detected and characterized by creating DNA microarrays with hundreds to thousands of complementary probe sequences immobilized on a single chip surface. However, the short sequence length of miRNAs (19-23mers) means that the methods used to detect messenger RNA with oligonucleotide microarrays cannot be used. In addition, direct PCR amplification of mature miRNAs cannot be used, making the ultrasensitive detection of miRNA at femtomolar concentrations particularly difficult. In this Minireview, we focus on the latest developments that overcome the various difficulties in the application of microarray-based detection platforms for the profiling of miRNA expression in biological samples. II. Challenges in miRNA profiling Microarray-based techniques are particularly attractive for miRNA profiling since they are able to screen large numbers of miRNAs simultaneously. However, miRNAs present several unique challenges that make them more difficult to analyze than conventional oligonucleotide microarray targets such as genomic DNA and messenger RNA. The short length of mature miRNAs provides very little sequence to work with for the design of complementary microarray probes. The duplex melting temperature (Tm) of each known miRNA and its complementary DNA strand varies widely and normalization of the hybridization efficiency for each microarray element cannot be achieved by simply reducing the length of some of the probe sequences. The short lengths of miRNAs also make it difficult to reliably amplify or label each miRNA without introducing signal bias. Furthermore, miRNAs represent only a small fraction (~0.01%) of the mass of a total RNA sample, with the relative expression levels between different miRNAs varying by as much as four orders of magnitude from a few copies to over 50,000 copies per cell.[2] It is also important to ensure that the non-active pri-miRNA and pre-miRNA precursor species do not contribute to the array detection signal. Efforts to improve the accuracy of miRNA profiling measurements have primarily focused on developing new strategies for (i) complementary probe design and (ii) miRNA labeling. Most miRNA studies reported to date have employed DNA capture probes resulting in conditions more reliable for comparing expression levels of the same miRNAs in different samples than actually for comparing the relative levels of different miRNAs in the same sample. To equalize the hybridization conditions without compromising specificity, several researchers have proposed incorporating modified nucleotides into the probe sequences[31, 32] or extending the length of the probe sequence-miRNA duplex interaction with additional base pairs introduced upon miRNA labeling.[34] Recently Castoldi et al[31] demonstrated the application of locked nucleic acids (LNAs) in place of conventional DNA probes. LNAs are commercially available nucleic acid analogs containing one or more modified nucleotide monomers where the ribose moiety is modified with an extra bridge connecting the 2′-O and 4′-C atoms. By controlling the number and location of modified nucleotides, the thermostability of each miRNA-LNA duplex can be significantly increased as well as making it possible to design a complete set of Tm-normalized probes that results in more accurate profiling. The increased binding affinity of LNA probes not only yields a ten-fold increase in sensitivity compared to unmodified DNA probes but also improves hybridization discrimination among closely related miRNAs.[31, 35] Another challenge in miRNA profiling is that conventional methods used to amplify or label longer RNA and DNA targets prior to detecting a microarray hybridization signal cannot be directly applied. In order to produce an accurate miRNA profile it is extremely important that the labeling method quantitatively reflects the abundance of different miRNAs present in the sample while maintaining the biological integrity and hybridization performance of the target miRNA. The specificity of the labeling assay towards mature miRNAs can also be improved through the use of commercially available miRNA enrichment kits (e.g. Ambion, Qiagen), which removes the precursor miRNAs and other larger RNA species. In the following sections we discuss a variety of chemical and enzymatic methods designed (a summary of which is shown in Table I) to directly attach a label or tag allowing sensitive detection. For comparison with labeling methods, examples of detection methods that do not involve miRNA modification prior to hybridization are also described.
III. Direct Detection of miRNA Despite the challenges described in the previous section, there are a handful of reports demonstrating direct multiplexed detection of miRNA with sensitivities comparable to or greater than northern blotting. By direct, we mean here the detection of miRNA without the need for chemical or enzymatic modification of the target molecules prior to analysis. Another very active area of non-multiplexed direct detection that we will not discuss in this review is the area of in-situ hybridization, where fluorescently labeled complementary locked nucleic acid (LNA) probes are used to directly visualize the specific location and evolution of a mature miRNA target within different organisms and tissue sections.[36-38] A number of direct detection methods have been developed for miRNA profiling applications, and are listed in Table I. In this section we describe two examples of direct multiplexed miRNA detection: (i) a solution-based sandwich assay format where the target miRNA simultaneously hybridizes to a pair of spectrally distinguishable fluorescent oligonucleotide probes, which are each complementary to one half of the target miRNA, and (ii) a surface-based assay directly measuring sequence specific adsorption (termed “hybridization adsorption”) onto complementary probe array elements created on the surface of a supported gold thin film. Solution-based direct multiplexed detection of miRNA A dual-probe hybridization scheme capable of directly detecting single miRNA molecules in solution was recently demonstrated by Neely et al.[39] Each probe is labeled with a different fluorescence tag and specifically binds to one half of the target miRNA (see Fig. 2
Surface-based direct multiplexed detection of miRNA The detection and identification of short, unlabeled RNA and DNA oligonucleotides can also be achieved in a microarray format using surface plasmon resonance imaging (SPRI). This is a surface-sensitive optical technique that has been widely applied to the real-time monitoring of various bioaffinity interactions (e.g. DNA-DNA, RNA-DNA, peptide-protein) at biopolymer layers formed on a thin gold film.[40] Although the SPRI detection limit for DNA and RNA analysis lies in the low nanomolar range,[41, 42] which is not as sensitive as fluorescence microarray measurements, SPRI analysis does provide valuable insights into the kinetics and thermodynamics limitations of the miRNA surface hybridization adsorption reaction. An example of the detection of RNA by hybridization adsorption onto DNA microarrays with SPRI is shown in Figure 3
The SPRI data in Figure 3 A second reason that it is difficult to detect low miRNA concentrations with microarrays is the kinetics of hybridization adsorption. The hybridization adsorption rate (ka) for miRNA is approximately 104M-1s-1. Since the velocity of the adsorption reaction can be described by kaC , the time required to reach an equilibrium surface coverage increases significantly as the concentration is lowered. In addition, there is also a diffusional contribution that becomes significant at lower concentrations due to the time required for the miRNA molecules to reach the surface array elements. For 10 fM detection, a minimum reaction time of ~4h is necessary to reach a steady-state coverage provided a circulating flow cell is used to minimize diffusion effects. At even lower concentrations and if a circulating flow cell is not used then longer reaction times will be required. Both the Langmuir adsorption equilibrium arguments and adsorption kinetics clearly demonstrate that the application of microarray based techniques to perform miRNA profiling require the use of an amplification technology. A variety of chemical and enzymatic assays designed to enhance the sensitivity of both fluorescence and SPRI based microarray measurements are discussed in the following sections. IV. Chemical modification strategies for multiplexed miRNA detection To achieve higher sensitivity in a miRNA assay, it is necessary to chemically or enzymatically modify the target miRNA species prior to detection. A list of the chemical modification strategies that have been used to date is given in Table I. The simplest method of chemical modification is to attach a fluorescent label directly onto the miRNA molecules. Figure 4
The use of a platinum dye complex that forms a stable adduct at the N7 position of any guanine base in the miRNA sequence (see Fig. 4a A second approach which also targets nucleotide bases in the miRNA sequence is shown in Figure 4(b) A third approach that has better control over the total number of labels attached to each miRNA, and which was developed originally for labeling mRNA by Weiler et al.[32, 44], is shown schematically in Figure 4(c) V. Solution Enzymatic Modification Strategies The most successful miRNA modification strategies to date for multiplexed miRNA detection employ enzymatic modification reactions, either in solution or directly on the microarray surface. Nucleic acid enzymes are often used in biotechnological applications as highly efficient tools for the amplification and site-selective manipulation of genomic DNA and RNA. One of the most widely used essential enzymatic reactions for miRNA modification is the lengthening of the target miRNA by catalyzing the addition of nucleotides to either the 3′ or 5′ ends; these extension reactions enable conventional techniques such as cloning and PCR-amplification to be employed for miRNA discovery and detection. Several solution-based enzymatic assays have been proposed for high-throughput miRNA proling using microarrays. A common approach used by several researchers is to ligate adapter oligonucleotide sequences to both the 3′ and 5′ ends of miRNA followed by reverse transcriptase (RT) to create a complementary DNA (cDNA) library. Further PCR amplification incorporating fluorescent probes is then performed prior to microarray analysis.[27, 28, 30] Although highly sensitive, this indirect approach to miRNA profiling requires extensive sample manipulation. We describe here three more convenient enzymatic assays designed to directly attach one or more labels to each target miRNA in solution. One of the most powerful enzymatic modification reactions applied to miRNA analysis is the use of T4 RNA ligase to covalently couple the 5′-end of a polynucleotide sequence of any desired length to the 3′-OH end of miRNA. This reaction was first applied by Thomson et al[24] to directly attach a fluorophore-conjugated dinucleotide to the miRNA pool prior to microarray hybridization. Figure 5(a)
Further enhancements in sensitivity have been investigated by instead using combined tailing/labeling procedures such as that shown in Figure 5(b) and (c) VI. Surface-based Enzymatic Modification Strategies There are several significant advantages if enzymatic modification strategies used to specifically label miRNA can be implemented directly on a microarray surface instead of in solution. One major advantage of a surface-based approach is that there is no sample manipulation before miRNA hybridization to the microarray. This avoids possible biases that could be introduced due to differential labeling between various miRNAs or sample loss during the labeling reaction and clean-up. Furthermore, multi-step reactions are easier to perform sequentially on a surface than in solution and only miRNAs hybridized to the surface are modified whereas in solution all RNA species are potentially labeled. Note that surface labeling will not work for the first two chemical reactions highlighted in Section IV, which are not specific to RNA and will also label the oligonucleotide probes attached to the microarray surface. In principle, the sodium periodate chemical reaction in Section IV should be amenable to the specific labeling of surface attached miRNAs but has not yet been demonstrated in a microarray format. In this section we describe two recent examples of miRNA detection based on surface enzyme reactions. Recently, we developed a novel approach that combines both a surface poly(A) polymerase reaction and DNA-modified nanoparticle enhancement for the ultrasensitive microarray detection of miRNAs using SPR imaging.[49] As outlined in Figure 6
The surface polyadenylation-nanoparticle amplification methodology was demonstrated with the multiplexed detection of three different miRNAs present in a total RNA sample extracted from mouse liver tissue. A four-component microarray was constructed containing three LNA probes designed to bind to the known miRNA sequences, miR-16, miR-122b, and miR-23b, with a DNA probe used as a negative control.[49] A 250 ng RNA sample in a volume of 500 μl was circulated over the microarray surface repeatedly for 4 hours followed by surface amplification. Analysis of the resulting SPRI difference image (Figure 7a
Another example of surface-based enzymatic amplification reaction for miRNA detection is the RNA-primed array-based Klenow enzyme assay (RAKE) approach.[25, 50, 51] This assay is based on the ability of a miRNA molecule to act as a primer for a Klenow polymerase extension reaction when the miRNA is fully base paired with a ssDNA probe. Providing there is no mismatch, the 3′-end of the miRNA is extended with biotin-conjugated nucleotides, the number of which depends on the DNA probe template. Streptavidin-conjugated fluorophores are then used to visualize and quantify the microarray elements containing hybridized and Klenow-extended miRNAs. The sensitivity of the RAKE assay was found to be comparable to other fluorescent-based microarray assays involving the direct attachment of a single label.[24] However, RAKE avoids sample manipulation procedures associated with labeling or amplification prior to hybridization and is also highly specific with superior discrimination between miRNAs that differ at their 3′-ends. VII. Summary and Outlook There is no doubt that the demand for rapid, high quality miRNA profiling will continue to increase exponentially as the complex roles of miRNAs in regulatory networks and human diseases become more understood. The ideal miRNA profiling technique will be easy to multiplex, have negligible sequence bias towards particular miRNAs, involve simple experimental protocols with minimum sample manipulation prior to hybridization, and have a large measurement dynamic range from sub-femtomolar to nanomolar concentrations. While this ultimate technique does not yet exist, recent developments utilizing microarray-based detection platforms in combination with various chemical and enzymatic miRNA-labeling strategies are very close to achieving this idealized goal. To date, most of the miRNA labeling reactions are performed in solution and require one or more reaction steps; more recent methods employ surface enzymatic reactions that can be easily cleaned up since the selective labeling of miRNAs occurs after hybridization adsorption onto the probe microarray surface. In addition, the new surface-based labeling strategies will most likely employ either multiple fluorophores or multiple nanoparticles with a single miRNA; however, some care will have to be taken since the signal levels of these detection methods are less controlled and quantifiable. In general, we expect that in the not too distant future a variety of new quantitative, ultrasensitive approaches for miRNA expression profiling using microarrays will amply fill the needs of researchers interested in the study of miRNA in biological systems. Acknowledgements We gratefully acknowledge funding support from the National Institutes of Health (2RO1 GM059622-04), the National Science Foundation (CHE-0551935) and the DARPA Micro/Nano Fluidics Fundamentals Focus (MF3) Center at UCI. References [1] Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T. RNA. 2003;9:277. [PubMed] [2] Bartel D. Cell. 2004;116:281. [PubMed] [3] He L, Hannon GJ. Nat. Rev. Genetics. 2004;5:522. [PubMed] [4] Kim VN. Nat. Rev. Mol. Cell Biol. 2005;6:376. [PubMed] [5] Pasquinelli AE, Hunter S, Bracht J. Curr. Opin. Genet. Dev. 2005;15:200. [PubMed] [7] Lee RC, Feinbaum RL, Ambros V. Cell. 1993;75:843. [PubMed] [8] Ambros V. Nature. 2004;431:350. [PubMed] [9] Carthew RW. Curr. Opin. Genet. Dev. 2006;16:203. [PubMed] [10] Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, Dongen SV, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright AJ, Dougan G, Turner M, Bradley A. Science. 2007;316:608. [PubMed] [11] Esquela-Kerscher A, Slack FJ. Nat. Rev. Cancer. 2006;6:259. [PubMed] [12] Calin GA, Croce CM. Nat. Rev. Cancer. 2006;6:857. [PubMed] [13] Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Nat. Genet. 2007;39:673. [PubMed] [14] Griffiths-Jones S. Nucl. Acids Res. 2004;32:D109. [PubMed] [15] Griffiths-Jones S, Grocock RJ, Dongen SV, Bateman A, Enright AJ. Nucl. Acids Res. 2006;34:D140. [PubMed] [16] Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, Sharon E, Spector Y, Bentwich Z. Nat. Genet. 2005;37:766. [PubMed] [17] Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foa R, Schliwka J, Fuchs U, Novosel A, Muller R-U, Schermer B, Bissels U, Inman J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter H-I, Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro R, Wernet P, Macino G, Rogler CE, Nagle JW, Ju J, Papavasiliou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A, Russo JJ, Sander C, Zavolan M, Tuschl T. Cell. 2007;129:1401. [PubMed] [18] Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Science. 2001;294:853. [PubMed] [19] Allawi HT, Dahlberg JE, Olson S, Lund E, Olson M, Ma W-P, Takova T, Neri BP, Lyamichev VI. RNA. 2004;10:1153. [PubMed] [20] Schmittgen TD, Jiang J, Liu Q, Yang L. Nucl. Acids Res. 2004;32:e43. [PubMed] [21] Raymond CK, Roberts BS, Garrett-Engele P, Lim LP, Johnson JM. RNA. 2005;11:1737. [PubMed] [22] Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ. Nucl. Acids Res. 2005;33:e179. [PubMed] [23] Babak T, Zhang W, Morris Q, Blencowe BJ, Hughes TR. RNA. 2004;10:1813. [PubMed] [24] Thomson JM, Parker J, Perou CM, Hammond SM. Nat. Methods. 2004;1:47. [PubMed] [25] Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW, Mourelatos Z. Nat. Methods. 2004;1:155. [PubMed] [26] Liu C-G, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD, Shimizu M, Zupo S, Dono M, Alder H, Bullrich F, Negrini M, Croce CM. Proc. Nat. Acad. Sci. U. S. A. 2004;101:9740. [27] Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I, Einav U, Gilad S, Hurban P, Karov Y, Lobenhofer EK, Sharon E, Shiboleth YM, Shtutman M, Z B, P E. Genome Res. 2004;14:2486. [PubMed] [28] Miska EA, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic P, Constantine-Paton M, Horvitz R. Genome Biol. 2004;5:R68. [PubMed] [29] Goff LA, Yang M, Bowers J, Getts RC, Padgett RW, Hart RP. RNA Biol. 2005;2:93. [PubMed] [30] Baskerville S, Bartel DP. RNA. 2005;11:241. [PubMed] [31] Castoldi M, Schmidt S, Benes V, Noerholm M, Kulozik AE, Hentze MW, Muckenthaler MU. RNA. 2006;12:913. [PubMed] [32] Beuvinky I, Kolb FA, Budach W, Garnier A, Lange J, Natt F, Dengler U, Hall J, Filipowicz W, Weiler J. Nucl. Acids Res. 2007;35:e52. [PubMed] [33] Lockhart DJ, Winzeler EA. Nature. 2000;405:827. [PubMed] [34] Wang H, Ach RA, Curry B. RNA. 2007;13:151. [PubMed] [35] Valoczi A, Hornyik C, Varga N, Burgyan J, Kauppinen S, Havelda Z. Nucl. Acids Res. 2004;32:e175. [PubMed] [36] Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, Bruijn ED, Horvitz HR, Kauppinen S, Plasterk RHA. Science. 2005;309:310. [PubMed] [37] Kloosterman WP, Wienholds E, Bruijn ED, Kauppinen S, Plasterk RHA. Nat. Methods. 2006;3:27. [PubMed] [38] Deo M, Yu J-Y, Chung K-H, Tippens M, Turner DL. Dev. Dynamics. 2006;235:2538. [39] Neely LA, Patel S, Garver J, Gallo M, Hackett M, McLaughlin S, Nadel M, Harris H, Gullans S, Rooke J. Nat. Methods. 2006;3:41. [PubMed] [40] Lee HJ, Wark AW, Corn RM. Langmuir. 2006;22:5241. [PubMed] [41] Wark AW, Lee HJ, Corn RM. Anal. Chem. 2005;77:3904. [PubMed] [42] Lee HJ, Li Y, Wark AW, Corn RM. Anal. Chem. 2005;77:5096. [PubMed] [43] Enos JM, Duzeski JL, Roesch PL, Hagstrom JE, Watt M-AV. Biotechniques. 2007;42:378. [44] Garnier A, Hüsken D, Weiler J. Nucleosides, Nucleotides & Nucleic Acids. 2001;20:1181. [45] Liang R, Li W, Li Y, Tan C, Li J, Jin Y, Ruan K. Nucl. Acids Res. 2005;33:e17. [PubMed] [46] Gao Z, Yang Z. Anal. Chem. 2006;78:1470. [PubMed] [47] Shingara J, Keiger K, Shelton J, Laosinchai-Wolf L, Powers P, Conrad R, Brown D, Labourier E. RNA. 2005;11:1461. [PubMed] [48] Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Mol. Cancer. 2006;5:24. [PubMed] [49] Fang S, Lee HJ, Wark AW, Corn RM. J. Am. Chem. Soc. 2006;128:14044. [PubMed] [50] Nelson PT, Baldwin DA, Kloosterman WP, Kauppinen S, Plasterk RHA, Mourelatos Z. RNA. 2006;12:187. [PubMed] [51] Berezikov E, Tetering GV, Verheul M, Belt JVD, Laake LV, Vos J, Verloop R, Wetering MVD, Guryev V, Takada S, Zonneveld AJV, Mano H, Plasterk R, Cuppen E. Genome Res. 2006;16:1289. [PubMed] [52] Ramkissoon SH, Mainwaring LA, Sloand EM, Young NS, Kajigaya S. Mol. Cell. Probes. 2006;20:1. [PubMed] [53] Hartig JS, Grune I, Najafi-Shoushtari SH, Famulok M. J. Am. Chem. Soc. 2004;126:722. [PubMed] [54] Chen PY, Manninga H, Slanchev K, Chien M, Russo JJ, Ju J, Sheridan R, John B, Marks DSS, Gaidatzis D, Sander C, Zavolan M, Tuschl T. Genes & Dev. 2005;19:1288. [PubMed] [55] He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. Nature. 2005;435:828. [PubMed] [56] Jonstrup SP, Koch J, Kjems J. RNA. 2006;12:1747. [PubMed] [57] Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. Nature. 2005;435:834. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||
RNA. 2003 Mar; 9(3):277-9.
[RNA. 2003]Cell. 2004 Jan 23; 116(2):281-97.
[Cell. 2004]Angew Chem Int Ed Engl. 2006 Aug 4; 45(31):5048-50.
[Angew Chem Int Ed Engl. 2006]Cell. 1993 Dec 3; 75(5):843-54.
[Cell. 1993]Nature. 2004 Sep 16; 431(7006):350-5.
[Nature. 2004]Science. 2007 Apr 27; 316(5824):608-11.
[Science. 2007]Nat Rev Cancer. 2006 Apr; 6(4):259-69.
[Nat Rev Cancer. 2006]Nat Rev Cancer. 2006 Nov; 6(11):857-66.
[Nat Rev Cancer. 2006]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D109-11.
[Nucleic Acids Res. 2004]Nucleic Acids Res. 2006 Jan 1; 34(Database issue):D140-4.
[Nucleic Acids Res. 2006]Cell. 2004 Jan 23; 116(2):281-97.
[Cell. 2004]Nat Genet. 2005 Jul; 37(7):766-70.
[Nat Genet. 2005]Cell. 2007 Jun 29; 129(7):1401-14.
[Cell. 2007]RNA. 2004 Nov; 10(11):1813-9.
[RNA. 2004]Nucleic Acids Res. 2007; 35(7):e52.
[Nucleic Acids Res. 2007]Nature. 2000 Jun 15; 405(6788):827-36.
[Nature. 2000]Cell. 2004 Jan 23; 116(2):281-97.
[Cell. 2004]RNA. 2006 May; 12(5):913-20.
[RNA. 2006]Nucleic Acids Res. 2007; 35(7):e52.
[Nucleic Acids Res. 2007]RNA. 2007 Jan; 13(1):151-9.
[RNA. 2007]Nucleic Acids Res. 2004 Dec 14; 32(22):e175.
[Nucleic Acids Res. 2004]Science. 2005 Jul 8; 309(5732):310-1.
[Science. 2005]Nat Methods. 2006 Jan; 3(1):41-6.
[Nat Methods. 2006]Langmuir. 2006 Jun 6; 22(12):5241-50.
[Langmuir. 2006]Anal Chem. 2005 Jul 1; 77(13):3904-7.
[Anal Chem. 2005]Anal Chem. 2005 Aug 15; 77(16):5096-100.
[Anal Chem. 2005]RNA. 2006 May; 12(5):913-20.
[RNA. 2006]RNA. 2004 Nov; 10(11):1813-9.
[RNA. 2004]Nucleic Acids Res. 2007; 35(7):e52.
[Nucleic Acids Res. 2007]Nucleic Acids Res. 2005 Jan 31; 33(2):e17.
[Nucleic Acids Res. 2005]Anal Chem. 2006 Mar 1; 78(5):1470-7.
[Anal Chem. 2006]Genome Res. 2004 Dec; 14(12):2486-94.
[Genome Res. 2004]Genome Biol. 2004; 5(9):R68.
[Genome Biol. 2004]RNA. 2005 Mar; 11(3):241-7.
[RNA. 2005]Nat Methods. 2004 Oct; 1(1):47-53.
[Nat Methods. 2004]RNA. 2007 Jan; 13(1):151-9.
[RNA. 2007]RNA. 2005 Sep; 11(9):1461-70.
[RNA. 2005]Mol Cancer. 2006 Jun 19; 5():24.
[Mol Cancer. 2006]J Am Chem Soc. 2006 Nov 1; 128(43):14044-6.
[J Am Chem Soc. 2006]J Am Chem Soc. 2006 Nov 1; 128(43):14044-6.
[J Am Chem Soc. 2006]Nat Methods. 2004 Nov; 1(2):155-61.
[Nat Methods. 2004]RNA. 2006 Feb; 12(2):187-91.
[RNA. 2006]Genome Res. 2006 Oct; 16(10):1289-98.
[Genome Res. 2006]Nat Methods. 2004 Oct; 1(1):47-53.
[Nat Methods. 2004]Nat Methods. 2006 Jan; 3(1):41-6.
[Nat Methods. 2006]J Am Chem Soc. 2006 Nov 1; 128(43):14044-6.
[J Am Chem Soc. 2006]J Am Chem Soc. 2006 Nov 1; 128(43):14044-6.
[J Am Chem Soc. 2006]